Report cover image

Global Recombinant Vector Vaccines Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 198 Pages
SKU # APRC20561335

Description

Summary

According to APO Research, The global Recombinant Vector Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Recombinant Vector Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Recombinant Vector Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Recombinant Vector Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Vector Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Recombinant Vector Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Recombinant Vector Vaccines sales, projected growth trends, production technology, application and end-user industry.


Recombinant Vector Vaccines Segment by Company


SANOFI PASTEUR S.A.
CNBG
SINOVAC BIOTECH
Zhifei
GSK
Hualan Bio
ChengDa Bio
NuoCheng Bio
Novartis
Kangtai
Changsheng Life

Recombinant Vector Vaccines Segment by Type


Varicella
Influenza
Hepatitis
Pneumococcal
Pertussis, Diphtheria, tetanus
Others

Recombinant Vector Vaccines Segment by Application


For Adult
For Child

Recombinant Vector Vaccines Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Recombinant Vector Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Vector Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Recombinant Vector Vaccines Market by Type
1.2.1 Global Recombinant Vector Vaccines Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Hepatitis
1.2.5 Pneumococcal
1.2.6 Pertussis, Diphtheria, tetanus
1.2.7 Others
1.3 Recombinant Vector Vaccines Market by Application
1.3.1 Global Recombinant Vector Vaccines Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 For Adult
1.3.3 For Child
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Recombinant Vector Vaccines Market Dynamics
2.1 Recombinant Vector Vaccines Industry Trends
2.2 Recombinant Vector Vaccines Industry Drivers
2.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
2.4 Recombinant Vector Vaccines Industry Restraints
3 Global Market Growth Prospects
3.1 Global Recombinant Vector Vaccines Revenue Estimates and Forecasts (2020-2031)
3.2 Global Recombinant Vector Vaccines Revenue by Region
3.2.1 Global Recombinant Vector Vaccines Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Recombinant Vector Vaccines Revenue by Region (2020-2025)
3.2.3 Global Recombinant Vector Vaccines Revenue by Region (2026-2031)
3.2.4 Global Recombinant Vector Vaccines Revenue Market Share by Region (2020-2031)
3.3 Global Recombinant Vector Vaccines Sales Estimates and Forecasts 2020-2031
3.4 Global Recombinant Vector Vaccines Sales by Region
3.4.1 Global Recombinant Vector Vaccines Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Recombinant Vector Vaccines Sales by Region (2020-2025)
3.4.3 Global Recombinant Vector Vaccines Sales by Region (2026-2031)
3.4.4 Global Recombinant Vector Vaccines Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Recombinant Vector Vaccines Revenue by Manufacturers
4.1.1 Global Recombinant Vector Vaccines Revenue by Manufacturers (2020-2025)
4.1.2 Global Recombinant Vector Vaccines Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Recombinant Vector Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Recombinant Vector Vaccines Sales by Manufacturers
4.2.1 Global Recombinant Vector Vaccines Sales by Manufacturers (2020-2025)
4.2.2 Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Recombinant Vector Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Recombinant Vector Vaccines Sales Price by Manufacturers (2020-2025)
4.4 Global Recombinant Vector Vaccines Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Recombinant Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Recombinant Vector Vaccines Manufacturers, Product Type & Application
4.7 Global Recombinant Vector Vaccines Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Recombinant Vector Vaccines Market CR5 and HHI
4.8.2 2024 Recombinant Vector Vaccines Tier 1, Tier 2, and Tier 3
5 Recombinant Vector Vaccines Market by Type
5.1 Global Recombinant Vector Vaccines Revenue by Type
5.1.1 Global Recombinant Vector Vaccines Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Recombinant Vector Vaccines Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2031)
5.2 Global Recombinant Vector Vaccines Sales by Type
5.2.1 Global Recombinant Vector Vaccines Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Recombinant Vector Vaccines Sales by Type (2020-2031) & (k units)
5.2.3 Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2031)
5.3 Global Recombinant Vector Vaccines Price by Type
6 Recombinant Vector Vaccines Market by Application
6.1 Global Recombinant Vector Vaccines Revenue by Application
6.1.1 Global Recombinant Vector Vaccines Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Recombinant Vector Vaccines Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2031)
6.2 Global Recombinant Vector Vaccines Sales by Application
6.2.1 Global Recombinant Vector Vaccines Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Recombinant Vector Vaccines Sales by Application (2020-2031) & (k units)
6.2.3 Global Recombinant Vector Vaccines Sales Market Share by Application (2020-2031)
6.3 Global Recombinant Vector Vaccines Price by Application
7 Company Profiles
7.1 SANOFI PASTEUR S.A.
7.1.1 SANOFI PASTEUR S.A. Comapny Information
7.1.2 SANOFI PASTEUR S.A. Business Overview
7.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
7.1.5 SANOFI PASTEUR S.A. Recent Developments
7.2 CNBG
7.2.1 CNBG Comapny Information
7.2.2 CNBG Business Overview
7.2.3 CNBG Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
7.2.5 CNBG Recent Developments
7.3 SINOVAC BIOTECH
7.3.1 SINOVAC BIOTECH Comapny Information
7.3.2 SINOVAC BIOTECH Business Overview
7.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
7.3.5 SINOVAC BIOTECH Recent Developments
7.4 Zhifei
7.4.1 Zhifei Comapny Information
7.4.2 Zhifei Business Overview
7.4.3 Zhifei Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
7.4.5 Zhifei Recent Developments
7.5 GSK
7.5.1 GSK Comapny Information
7.5.2 GSK Business Overview
7.5.3 GSK Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 GSK Recombinant Vector Vaccines Product Portfolio
7.5.5 GSK Recent Developments
7.6 Hualan Bio
7.6.1 Hualan Bio Comapny Information
7.6.2 Hualan Bio Business Overview
7.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
7.6.5 Hualan Bio Recent Developments
7.7 ChengDa Bio
7.7.1 ChengDa Bio Comapny Information
7.7.2 ChengDa Bio Business Overview
7.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
7.7.5 ChengDa Bio Recent Developments
7.8 NuoCheng Bio
7.8.1 NuoCheng Bio Comapny Information
7.8.2 NuoCheng Bio Business Overview
7.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
7.8.5 NuoCheng Bio Recent Developments
7.9 Novartis
7.9.1 Novartis Comapny Information
7.9.2 Novartis Business Overview
7.9.3 Novartis Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
7.9.5 Novartis Recent Developments
7.10 Kangtai
7.10.1 Kangtai Comapny Information
7.10.2 Kangtai Business Overview
7.10.3 Kangtai Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
7.10.5 Kangtai Recent Developments
7.11 Changsheng Life
7.11.1 Changsheng Life Comapny Information
7.11.2 Changsheng Life Business Overview
7.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
7.11.5 Changsheng Life Recent Developments
8 North America
8.1 North America Recombinant Vector Vaccines Market Size by Type
8.1.1 North America Recombinant Vector Vaccines Revenue by Type (2020-2031)
8.1.2 North America Recombinant Vector Vaccines Sales by Type (2020-2031)
8.1.3 North America Recombinant Vector Vaccines Price by Type (2020-2031)
8.2 North America Recombinant Vector Vaccines Market Size by Application
8.2.1 North America Recombinant Vector Vaccines Revenue by Application (2020-2031)
8.2.2 North America Recombinant Vector Vaccines Sales by Application (2020-2031)
8.2.3 North America Recombinant Vector Vaccines Price by Application (2020-2031)
8.3 North America Recombinant Vector Vaccines Market Size by Country
8.3.1 North America Recombinant Vector Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Recombinant Vector Vaccines Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Recombinant Vector Vaccines Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Recombinant Vector Vaccines Market Size by Type
9.1.1 Europe Recombinant Vector Vaccines Revenue by Type (2020-2031)
9.1.2 Europe Recombinant Vector Vaccines Sales by Type (2020-2031)
9.1.3 Europe Recombinant Vector Vaccines Price by Type (2020-2031)
9.2 Europe Recombinant Vector Vaccines Market Size by Application
9.2.1 Europe Recombinant Vector Vaccines Revenue by Application (2020-2031)
9.2.2 Europe Recombinant Vector Vaccines Sales by Application (2020-2031)
9.2.3 Europe Recombinant Vector Vaccines Price by Application (2020-2031)
9.3 Europe Recombinant Vector Vaccines Market Size by Country
9.3.1 Europe Recombinant Vector Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Recombinant Vector Vaccines Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Recombinant Vector Vaccines Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Recombinant Vector Vaccines Market Size by Type
10.1.1 China Recombinant Vector Vaccines Revenue by Type (2020-2031)
10.1.2 China Recombinant Vector Vaccines Sales by Type (2020-2031)
10.1.3 China Recombinant Vector Vaccines Price by Type (2020-2031)
10.2 China Recombinant Vector Vaccines Market Size by Application
10.2.1 China Recombinant Vector Vaccines Revenue by Application (2020-2031)
10.2.2 China Recombinant Vector Vaccines Sales by Application (2020-2031)
10.2.3 China Recombinant Vector Vaccines Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Recombinant Vector Vaccines Market Size by Type
11.1.1 Asia Recombinant Vector Vaccines Revenue by Type (2020-2031)
11.1.2 Asia Recombinant Vector Vaccines Sales by Type (2020-2031)
11.1.3 Asia Recombinant Vector Vaccines Price by Type (2020-2031)
11.2 Asia Recombinant Vector Vaccines Market Size by Application
11.2.1 Asia Recombinant Vector Vaccines Revenue by Application (2020-2031)
11.2.2 Asia Recombinant Vector Vaccines Sales by Application (2020-2031)
11.2.3 Asia Recombinant Vector Vaccines Price by Application (2020-2031)
11.3 Asia Recombinant Vector Vaccines Market Size by Country
11.3.1 Asia Recombinant Vector Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Recombinant Vector Vaccines Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Recombinant Vector Vaccines Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Recombinant Vector Vaccines Market Size by Type
12.1.1 SAMEA Recombinant Vector Vaccines Revenue by Type (2020-2031)
12.1.2 SAMEA Recombinant Vector Vaccines Sales by Type (2020-2031)
12.1.3 SAMEA Recombinant Vector Vaccines Price by Type (2020-2031)
12.2 SAMEA Recombinant Vector Vaccines Market Size by Application
12.2.1 SAMEA Recombinant Vector Vaccines Revenue by Application (2020-2031)
12.2.2 SAMEA Recombinant Vector Vaccines Sales by Application (2020-2031)
12.2.3 SAMEA Recombinant Vector Vaccines Price by Application (2020-2031)
12.3 SAMEA Recombinant Vector Vaccines Market Size by Country
12.3.1 SAMEA Recombinant Vector Vaccines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Recombinant Vector Vaccines Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Recombinant Vector Vaccines Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Recombinant Vector Vaccines Value Chain Analysis
13.1.1 Recombinant Vector Vaccines Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Recombinant Vector Vaccines Production Mode & Process
13.2 Recombinant Vector Vaccines Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Recombinant Vector Vaccines Distributors
13.2.3 Recombinant Vector Vaccines Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.